Skip to content
Gold Mining News – Lifestyle
Author:
ViroMissile, Inc.
ViroMissile Completes First Dose Cohort of Phase I Trial of Intravenously-Dosed IDOV-2; Safety Review Committee Clears Advancement to Next Cohort
October 1, 2026
ViroMissile IDOV-Safe Phase 1 Data to Be Presented at the 2026 ASCO Annual Meeting
May 27, 2026